GlobalData forecasts osteoarthritis market to reach $9.8 billion by 2035

The 7MM osteoarthritis market is projected to grow at a CAGR of 9.4% from $3.9 billion in 2025, driven by an increase in diagnosed and treated patients and the launch of pipeline therapies

The osteoarthritis (OA) market across the seven major markets (7MM) is forecast to grow at a compound annual growth rate (CAGR) of 9.4%, from $3.9 billion in 2025 to $9.8 billion in 2035, according to GlobalData.

GlobalData’s report, “Osteoarthritis: Disease Analysis Report and Forecast 2025–35,” states that the projected growth will be driven by an increase in the diagnosed and treated OA population, resulting from ageing populations and rising obesity, as well as the launch of late-stage pipeline assets with novel mechanisms of action (MOAs).

Vinie Varkey, Healthcare Analyst at GlobalData, said, “These novel drug classes, spanning regenerative cell therapies, tissue-derived biologics, gene therapies, and other novel-MOA agents, are forecast to add around $5.2 billion in new sales by 2035, representing more than half of the total 7MM market. The US will remain the largest market, accounting for approximately 86% of 7MM sales throughout the forecast period, while Japan is the fastest-growing market at a 16.5% CAGR.”

In 2025, the OA market was dominated by established, largely genericised symptomatic therapies, including oral and topical non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and hyaluronic acid, alongside the branded long-acting intra-articular (IA) steroid Zilretta (triamcinolone acetonide). These drug classes are low-cost and mostly off-patent, and are expected to record modest growth despite high patient volumes.

Varkey added, “OA continues to be managed symptomatically, with no disease-modifying drugs approved and treatment ranging from non-pharmacological measures, such as exercise and weight loss, through topical and oral NSAIDs and IA corticosteroid injections, to joint replacement for refractory disease. The most transformative shift over the forecast window is the anticipated arrival of glucagon-like peptide-1 (GLP-1) receptor agonists, which now carry a conditional American College of Rheumatology (ACR) 2026 recommendation.”

According to GlobalData, the most significant unmet need identified by the key opinion leaders (KOLs) interviewed for the report was the absence of a disease-modifying OA drug (DMOAD) capable of halting disease progression. This remains the main gap in a market dominated by symptomatic, genericised treatments.

The KOLs also highlighted the need for analgesics with improved efficacy and safety profiles, therapies for the OA population with comorbidities, and better adherence to non-pharmacological care. Until treatments target the underlying drivers of the disease, OA will remain an indication that is managed rather than modified.

The late-stage OA pipeline comprises 42 products in active development, from Phase I to pre-registration, across the 7MM, with a focus on IA regenerative approaches. Regenerative cell therapy is expected to become the largest drug class by 2035 and includes allogeneic and autologous cell therapies such as CARTISTEM and JointStem.

Varkey concluded, “The OA market, while expected to grow rapidly, will still be constrained by several barriers. The landscape is heavily genericized, with low-cost established therapies setting a price bar that premium-priced novel agents must clear to gain access. As a result, GlobalData anticipates that payers will apply strict prior authorization, step therapy, and limited reimbursement to high-priced pipeline assets, restricting their uptake.”

7MM: The US, France, Germany, Italy, Spain, the UK, and Japan.

 

disease-modifying osteoarthritis drugsGlobalData reportosteoarthritis drug pipelineosteoarthritis marketosteoarthritis treatment
Comments (0)
Add Comment